Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">GW Pharma Q1 earnings call highlights (120.76)<ul><li>Sees very focused attention on FY17 pricing, reimbursement, & contracting strategies.</li><li>Continues to expect FY17 total cash outflows between $130-150 mln; co expects FY17 operating spend between $120-130 mln.</li><li><strong>Co notes the Epidiolex trial remains on track, expects an early 2018 US launch with a European launch to follow shortly after.</strong></li><li>An NDA submission for both Dravet and LGS indications is expected in mid 2017; preparations advancing for expected EU regulatory submission in H2 2017.</li><li>Co reviewed their glioblastoma exploratory phase II top-line results; study showed that patients with documented recurrent GBM treated with THC:CBD had an 83% one year survival rate compared with 53% for patients in the placebo cohort.</li></ul><p> — Shares of <strong>GWPH</strong> -2.0% pre-market.</p></td> </tr></table>"